A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Ciclopirox phosphoryloxymethyl ester (Primary)
- Indications Bladder cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors CicloMed
- 08 Feb 2018 Status changed from not yet recruiting to recruiting.
- 30 Nov 2017 New trial record
- 11 Oct 2017 According to a CicloMed LLC media release, Ciclopirox Prodrug, was cleared by the U.S. Food and Drug Administration to begin human clinical trials.